<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449722</url>
  </required_header>
  <id_info>
    <org_study_id>SAG-26/UCA</org_study_id>
    <secondary_id>2004-001216-31</secondary_id>
    <nct_id>NCT00449722</nct_id>
  </id_info>
  <brief_title>OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis</brief_title>
  <official_title>Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing
      of total 3.0 g mesalazine granules in patients with active ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical remission</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to resolution of symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of endoscopical remission</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of endoscopical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of histological remission</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of histological response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA</measure>
  </secondary_outcome>
  <enrollment>380</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalazine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (main):

          -  Active ulcerative colitis except proctitis, i.e. inflammation minimal 15cm ab ano,
             confirmed by endoscopy and histology

          -  Established or new diagnosis

          -  Disease activity at baseline: Clinical Activity Index (CAI) &gt;4 and Endoscopic Index
             (EI) &gt;= 4

        Exclusion Criteria (main):

          -  Crohn's disease

          -  Toxic megacolon

          -  Present or past colorectal cancer

          -  Symptomatic gastrointestinal disease

          -  Serious secondary disease(s)

          -  Baseline stool positive for germs causing bowel disease

          -  Immunosuppressants within 3 months and/or corticosteroids within 1 month prior to
             baseline

          -  Current relapse occurred under maintenance treatment with &gt;2g/day mesalazine

          -  Serum creatinine &gt;= 1.2x upper limit of normal (ULN) and creatinine clearance &lt; 60
             ml/min per 1.73 m2

          -  Serum transaminase (ALT and/or AST), and/or alkaline phosphatase &gt;= 2x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Kruis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evangelisches Krankenhaus Kalk, Cologne, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Kalk</name>
      <address>
        <city>Cologne</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Kruis W, Kiudelis G, RÃ¡cz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009 Feb;58(2):233-40. doi: 10.1136/gut.2008.154302. Epub 2008 Oct 2.</citation>
    <PMID>18832520</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

